{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mikami T"],"funding":["Kyoto University","The Kyoto University Foundation","Princess Takamatsu Cancer Research Fund","Friends of Leukemia Research Fund","Takeda Science Foundation","Japan Agency for Medical Research and Development","The Mother and Child Health Foundation","Child Health Foundation","Japan Society for the Promotion of Science"],"pagination":["102576"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12923955"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(2)"],"pubmed_abstract":["Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy is highly effective for B cell precursor acute lymphoblastic leukemia (BCP-ALL); however, approximately half of the patients relapse. Thus, there is an urgent need to identify factors that improve efficacy. This study enrolls 19 patients with BCP-ALL (16 children and 3 young adults) who receive tisagenlecleucel. Infusion products, peripheral blood, and bone marrow samples are obtained before and after CAR-T cell infusion. Single-cell analysis reveals that central memory CAR<sup>pos</sup> T cells increase in long-term responders, whereas CXCR3<sup>+</sup>CD38<sup>high</sup>PD-1<sup>high</sup> effector CAR<sup>pos</sup> T cells are enriched in relapsed patients, post-infusion. By contrast, CAR<sup>pos</sup> T cells obtained from infu"],"journal":["Cell reports. Medicine"],"pubmed_title":["CAR-T cells with the CD38&lt;sup&gt;-&lt;/sup&gt;CD73&lt;sup&gt;-&lt;/sup&gt;Tim-3&lt;sup&gt;-&lt;/sup&gt;HLA-DR&lt;sup&gt;+&lt;/sup&gt; phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL."],"pmcid":["PMC12923955"],"funding_grant_id":["23ama221505h0002","24ama221531h0001","25ama221531h0002","JP21ck0106531","JP24H00628","JP21K19405","23ama221514h002","JP23K18264","JP20H00528","22ama221514h0001","JP22K07211"],"pubmed_authors":["Llamas-Covarrubias MA","Umeda K","Wing JB","Saida S","Mikami T","Takita J","Kato I","Kitawaki T","Mitsuyoshi T","Uchihara Y","Takaori-Kondo A","Hiramatsu H","Ogawa S"],"additional_accession":[]},"is_claimable":false,"name":"CAR-T cells with the CD38&lt;sup&gt;-&lt;/sup&gt;CD73&lt;sup&gt;-&lt;/sup&gt;Tim-3&lt;sup&gt;-&lt;/sup&gt;HLA-DR&lt;sup&gt;+&lt;/sup&gt; phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.","description":"Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy is highly effective for B cell precursor acute lymphoblastic leukemia (BCP-ALL); however, approximately half of the patients relapse. Thus, there is an urgent need to identify factors that improve efficacy. This study enrolls 19 patients with BCP-ALL (16 children and 3 young adults) who receive tisagenlecleucel. Infusion products, peripheral blood, and bone marrow samples are obtained before and after CAR-T cell infusion. Single-cell analysis reveals that central memory CAR<sup>pos</sup> T cells increase in long-term responders, whereas CXCR3<sup>+</sup>CD38<sup>high</sup>PD-1<sup>high</sup> effector CAR<sup>pos</sup> T cells are enriched in relapsed patients, post-infusion. By contrast, CAR<sup>pos</sup> T cells obtained from infu","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T15:13:27.932Z","creation":"2026-07-10T03:09:18.564Z"},"accession":"S-EPMC12923955","cross_references":{"pubmed":["41579860"],"doi":["10.1016/j.xcrm.2025.102576"]}}